Scotts Miracle-Gro (SMG) Form 144 Reports $3.59M Planned Share Sale
Rhea-AI Filing Summary
The Scotts Miracle-Gro Company (SMG) filed a Form 144 reporting a proposed sale of common stock. The notice lists 56,633 shares to be sold through Merrill on 09/05/2025 with an aggregate market value of $3,586,987. The filing shows these shares were originally acquired on 06/16/1995 as a partnership contribution from Community Fund & General Partnership and paid in stock. It also discloses a sale during the past three months: the Hagedorn Partnership sold 70,000 shares on 08/04/2025 for $4,321,000. The filing includes the seller's representation that they possess no undisclosed material adverse information about the issuer.
Positive
- Disclosure completeness: The Form 144 provides broker details, sale date, share counts, and aggregate values
- Acquisition history provided: Original acquisition date (06/16/1995) and nature (partnership contribution) are disclosed
Negative
- Recent selling activity: A 70,000-share sale on 08/04/2025 for $4,321,000 indicates ongoing dispositions by related parties
- Planned sale size: 56,633 shares valued at $3,586,987 will be sold on 09/05/2025 (may affect short-term float)
Insights
TL;DR: Routine insider notice showing a modest planned sale and a recent 70,000-share sale; appears informational, not clearly material.
The Form 144 documents an intended sale of 56,633 common shares valued at $3.587 million, representing about 0.098% of the stated 57,738,577 shares outstanding. The filing also records a prior sale of 70,000 shares on 08/04/2025 for $4.321 million. From a trading-impact perspective, these sizes are small relative to the total share count and likely to be routine monetization by a holder whose position dates to 1995. The notice meets disclosure requirements and includes the standard attestation regarding material nonpublic information.
TL;DR: Compliance-focused Form 144 that documents insider selling and acquisition history without raising clear governance red flags.
The filing provides acquisition provenance (partnership contribution in 1995) and details of broker, timing, and proceeds for recent sales, which supports transparency for shareholders and regulators. The seller’s representation that no undisclosed material adverse information exists is included, as required. There is evidence of prior disposition activity in August 2025, which governance reviewers will log but which does not, by itself, indicate noncompliance or material governance concerns based on the disclosed facts alone.